Karimah Es Sabar sold $3.5M of CAPR
director at CAPRICOR THERAPEUTICS, INC.. 115,000 shares at an average of $30.57, traded Mar 31, 2026, filed Apr 1, 2026.
Score components
- +15RoleDirector
- +25Trade size$3.5M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.6%, 3m -23.4%, 6m -68.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001873796-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | MOption exercise Common Stock10b5-1 | +61,265 | $4.86 | $298k | 61,265 | Apr 1, 2026 |
| Mar 31, 2026 | SOpen-market sale Common Stock10b5-1 | -61,265 | $30.17 | $1.8M | 0 | Apr 1, 2026 |
| Apr 1, 2026 | MOption exercise Common Stock10b5-1 | +53,735 | $4.86 | $261k | 53,735 | Apr 1, 2026 |
| Apr 1, 2026 | SOpen-market sale Common Stock10b5-1 | -53,735 | $31.03 | $1.7M | 0 | Apr 1, 2026 |
| Mar 31, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -61,265 | $0.00 | $0 | 53,735 | Apr 1, 2026 |
| Apr 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -53,735 | $0.00 | $0 | 0 | Apr 1, 2026 |
Related signals
Other insiders at CAPRICOR THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $732k 24,100 shares | -68% | |
| 19Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $732k 24,100 shares | -44% | |
| 0Weak | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $27k 900 shares | -8% | |
| 0Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $27k 900 shares | -3% | |
| 37Weak | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $793k 25,000 shares | -75% | |
| 20Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $793k 25,000 shares | -45% | |
| 28Weak | CAPRICOR THERAPEUTICS, INC. | Karimah Es Sabar director | $241k 7,529 shares | -100% | |
| 44Moderate | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $753k 25,000 shares | -75% | |
| 27Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $753k 25,000 shares | -45% | |
| 46Moderate | CAPRbuy CAPRICOR THERAPEUTICS, INC. | Nippon Shinyaku Co Ltd owner | $15M 2,798,507 shares | +65% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.